Article
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Journal for ImmunoTherapy of Cancer
(2020)
Disciplines
Publication Date
November 1, 2020
DOI
10.1136/JITC-2020-SITC2020.0760
Citation Information
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, et al.. "760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab" Journal for ImmunoTherapy of Cancer Vol. 8 (2020) Available at: http://works.bepress.com/brian-piening/10/